Rani Therapeutics Q1 net loss narrows to $8M; Nasdaq bid price non-compliance; CFO to depart

Rani Therapeutics Holdings, Inc.

Q1 net loss $8.0M, narrowed from $12.7M YoY; cash $43.4M expected to fund operations into Q4 2027.
Received Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until Nov 9, 2026.
CFO Svai Sanford to resign after successor appointed; separation includes 9 months salary ($491,400) and accelerated vesting.
Phase 1 study of oral GLP-1/GLP-2 dual agonist RT-114 ongoing in obesity; partnered with ProGen.
Appointed new CTO, Head of Strategy, and Strategic Advisor in Q1 2026.

item 2.02item 3.01item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.